Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AMG 176 + Venetoclax|
AMG 176 selectively binds and inhibits Mcl1, which results in activation of apoptotic signaling, potentially leading to decreased tumor cell viability (Cancer Res July 1 2017 (77) (13 Supplement) 2027).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMG 176||Tapotoclax|AMG-176|AMG176||MCL1 Inhibitor 18||Tapotoclax (AMG 176) selectively inhibits MCL1, potentially resulting in increased tumor cell apoptosis (PMID: 31937611) and reduced tumor growth (PMID: 30254093).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119|Venclyxto||BCL2 inhibitor 25||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03797261||Phase I||AMG 176 + Venetoclax||A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies||Terminated||USA | DEU||1|